Beyond Air (NASDAQ:XAIR) Posts Earnings Results, Misses Estimates By $0.03 EPS

Beyond Air (NASDAQ:XAIR) released its quarterly earnings results on Tuesday. The company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.03), Zacks reports. Beyond Air had a negative net margin of 880.72% and a negative return on equity of 203.74%. The firm had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.75 million. Beyond Air updated its FY 2026 guidance to EPS.

Beyond Air Stock Performance

Shares of XAIR stock opened at $2.45 on Thursday. The firm has a market cap of $11.37 million, a price-to-earnings ratio of -0.21 and a beta of 0.25. The company has a debt-to-equity ratio of 0.64, a quick ratio of 2.72 and a current ratio of 3.20. Beyond Air has a 52 week low of $2.22 and a 52 week high of $13.52. The firm’s 50-day simple moving average is $3.47 and its two-hundred day simple moving average is $4.67.

Institutional Trading of Beyond Air

An institutional investor recently raised its position in Beyond Air stock. Geode Capital Management LLC boosted its stake in Beyond Air, Inc. (NASDAQ:XAIR) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 838,319 shares of the company’s stock after acquiring an additional 12,598 shares during the period. Geode Capital Management LLC owned 18.07% of Beyond Air worth $144,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 31.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on XAIR shares. D. Boral Capital reissued a “buy” rating and set a $11.00 price target on shares of Beyond Air in a research report on Wednesday. D Boral Capital raised shares of Beyond Air to a “strong-buy” rating in a research report on Thursday, July 17th. Finally, Wall Street Zen raised shares of Beyond Air from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $25.50.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.